Andrew E Kummer1, Morgan Grams2, Pamela Lutsey3, Yuan Chen2, Kunihiro Matsushita2, Anna Köttgen4, Aaron R Folsom3, Josef Coresh2. 1. Divisions of Renal Diseases and Hypertension and kumm0012@umn.edu. 2. Department of Epidemiology, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, Maryland; and. 3. Epidemiology and Community Health, School of Public Health, University of Minnesota, Minneapolis, Minnesota; 4. Department of Epidemiology, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, Maryland; and Freiburg University Medical Center, Freiburg, Germany.
Abstract
BACKGROUND AND OBJECTIVES: Previous studies demonstrated a higher risk of CKD in persons with a history of kidney stones, but these studies examined mostly white populations and did not evaluate important potential interactions such as race and plasma uric acid. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: In 10,678 Atherosclerosis Risk in Communities (ARIC) study participants free of CKD at baseline (ARIC visit 4 in 1996-1998), we assessed the association between a history of nephrolithiasis (a time-varying variable, defined by a combination of self-report and diagnostic codes) and incident CKD (defined by diagnostic codes from linkage to hospitalizations and US Centers for Medicare and Medicaid Services' records). RESULTS: At baseline, 856 participants had a history of nephrolithiasis; 322 developed nephrolithiasis during follow-up. Over a mean follow-up of 12 years, there were 1037 incident CKD events. Nephrolithiasis history was associated with a 29% (hazard ratio [HR], 1.29; 95% confidence interval [95% CI], 1.07 to 1.54) higher risk of CKD in demographic-adjusted analyses, but the association was no longer statistically significant after multivariable adjustment (HR, 1.09; 95% CI, 0.90 to 1.32). The multivariable-adjusted association was stronger among participants with plasma uric acid levels ≤6 mg/dl (HR, 1.34; 95% CI, 1.05 to 1.72) compared with those with levels >6 mg/dl (HR, 0.94; 95% CI, 0.70 to 1.28; P(interaction) = 0.05). There was no interaction of stone disease and race with incident CKD. CONCLUSIONS: In this community-based cohort, nephrolithiasis was not an independent risk factor for incident CKD overall. However, risk of CKD was unexpectedly elevated in participants with stone disease and lower plasma uric acid levels.
BACKGROUND AND OBJECTIVES: Previous studies demonstrated a higher risk of CKD in persons with a history of kidney stones, but these studies examined mostly white populations and did not evaluate important potential interactions such as race and plasma uric acid. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: In 10,678 Atherosclerosis Risk in Communities (ARIC) study participants free of CKD at baseline (ARIC visit 4 in 1996-1998), we assessed the association between a history of nephrolithiasis (a time-varying variable, defined by a combination of self-report and diagnostic codes) and incident CKD (defined by diagnostic codes from linkage to hospitalizations and US Centers for Medicare and Medicaid Services' records). RESULTS: At baseline, 856 participants had a history of nephrolithiasis; 322 developed nephrolithiasis during follow-up. Over a mean follow-up of 12 years, there were 1037 incident CKD events. Nephrolithiasis history was associated with a 29% (hazard ratio [HR], 1.29; 95% confidence interval [95% CI], 1.07 to 1.54) higher risk of CKD in demographic-adjusted analyses, but the association was no longer statistically significant after multivariable adjustment (HR, 1.09; 95% CI, 0.90 to 1.32). The multivariable-adjusted association was stronger among participants with plasma uric acid levels ≤6 mg/dl (HR, 1.34; 95% CI, 1.05 to 1.72) compared with those with levels >6 mg/dl (HR, 0.94; 95% CI, 0.70 to 1.28; P(interaction) = 0.05). There was no interaction of stone disease and race with incident CKD. CONCLUSIONS: In this community-based cohort, nephrolithiasis was not an independent risk factor for incident CKD overall. However, risk of CKD was unexpectedly elevated in participants with stone disease and lower plasma uric acid levels.
Authors: Boyd R Viers; John C Lieske; Terri J Vrtiska; Loren P Herrera Hernandez; Lisa E Vaughan; Ramilia A Mehta; Eric J Bergstralh; Andrew D Rule; David R Holmes; Amy E Krambeck Journal: Urology Date: 2015-02-11 Impact factor: 2.649
Authors: R Todd Alexander; Brenda R Hemmelgarn; Natasha Wiebe; Aminu Bello; Susan Samuel; Scott W Klarenbach; Gary C Curhan; Marcello Tonelli Journal: Clin J Am Soc Nephrol Date: 2013-12-05 Impact factor: 8.237
Authors: Ziad M El-Zoghby; John C Lieske; Robert N Foley; Eric J Bergstralh; Xujian Li; L Joseph Melton; Amy E Krambeck; Andrew D Rule Journal: Clin J Am Soc Nephrol Date: 2012-06-28 Impact factor: 8.237
Authors: Morgan E Grams; Casey M Rebholz; Blaithin McMahon; Seamus Whelton; Shoshana H Ballew; Elizabeth Selvin; Lisa Wruck; Josef Coresh Journal: Am J Kidney Dis Date: 2014-04-13 Impact factor: 8.860
Authors: Pietro Manuel Ferraro; Eric N Taylor; Brian H Eisner; Giovanni Gambaro; Eric B Rimm; Kenneth J Mukamal; Gary C Curhan Journal: JAMA Date: 2013-07-24 Impact factor: 56.272
Authors: R Todd Alexander; Brenda R Hemmelgarn; Natasha Wiebe; Aminu Bello; Catherine Morgan; Susan Samuel; Scott W Klarenbach; Gary C Curhan; Marcello Tonelli Journal: BMJ Date: 2012-08-29
Authors: William E Haley; Felicity T Enders; Lisa E Vaughan; Ramila A Mehta; Maxton E Thoman; Terri J Vrtiska; Amy E Krambeck; John C Lieske; Andrew D Rule Journal: Mayo Clin Proc Date: 2016-10-21 Impact factor: 7.616
Authors: Krista L Lentine; Bertram L Kasiske; Andrew S Levey; Patricia L Adams; Josefina Alberú; Mohamed A Bakr; Lorenzo Gallon; Catherine A Garvey; Sandeep Guleria; Philip Kam-Tao Li; Dorry L Segev; Sandra J Taler; Kazunari Tanabe; Linda Wright; Martin G Zeier; Michael Cheung; Amit X Garg Journal: Transplantation Date: 2017-08 Impact factor: 4.939
Authors: Casey M Rebholz; Deidra C Crews; Morgan E Grams; Lyn M Steffen; Andrew S Levey; Edgar R Miller; Lawrence J Appel; Josef Coresh Journal: Am J Kidney Dis Date: 2016-08-09 Impact factor: 8.860